Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

R-ICE regimen

View Patient Information
A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ICE plus rituximab
ifosfamide/carboplatin/etoposide/rituximab
RICE regimen
rituximab-ifosfamide-carboplatin-etoposide regimen
rituximab/ifosfamide/carboplatin/etoposide
rituximab/ifosfamide/carboplatin/etoposide regimen
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search